Management of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both

Radiation Oncology

Osama Youssef¹  Mohamed Mahmoud¹  Hesham A El Hossieny¹  Hoda M Abd El Baky¹  Mahmoud M El Gantery¹ 

[1] The Department of Radiation Oncology, National Cancer Institute, Cairo University, Cairo, Egypt

关键词: Brain metastases;    Radiotherapy;    Stereotaxy;    Whole brain irradiation;   

Others  :  803993
DOI  :  10.1186/1748-717X-9-116

 received in 2014-01-24, accepted in 2014-05-03,  发布年份 2014

【 摘 要 】

Introduction

This prospective randomized study aimed to evaluate the role of WBRT + SRS compared to SRS alone and to WBRT alone in improvement of overall survival, brain local control and neurologic manifestations.

Patients and methods

The trial included 60 patients with 1 to 3 brain metastases treated at the Radiotherapy Department, National Cancer Institute. 21 patients received WBRT + SRS, 18 patients received SRS alone and 21 patients received WBRT alone.

Results

Median local control was significantly better for WBRT + SRS compared to SRS alone & WBRT alone (10 vs 6 vs 5 months, respectively, P = 0.04). There was non significant survival benefit for WBRT + SRS compared to SRS alone & WBRT alone. Survival was significantly better for patients with controlled primary tumor who received WBRT + SRS compared to SRS alone & WBRT alone (median survival was 12 vs 5.5 vs 8 months, respectively. P = 0.027). Regardless of the treatment group, median survival and median local control were highly significantly better for single brain site involvement compared to multiple brain sites involvement (P = 0.003 & P = 0.001, respectively), and median brain local control was significantly better for single lesion compared to multiple lesions (P = 0.05).

Conclusions

WBRT + SRS is an effective, safe tool in treatment of patients with 1 to 3 brain metastses improving the brain local control, but further studies with larger number of patients is recommended.

【 授权许可】

   
2014 El Gantery et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Posner JB: Management of brain metastases. Rev Neurol (Paris) 1992, 148(6–7):477-487.
• [2]Wen PY, Loeffler JS: Management of brain metastases. Oncology (Williston Park) 1999, 13(7):941-954. 957–962, 969
• [3]Loeffler JS, Patchell RA, Sawaya R: Treatment of metastatic cancer. In Cancer: Principles and Practice of Oncology. 5th edition. Edited by Devita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott-Raven; 1997:2523-2525.
• [4]Eichler AF, Loeffler JS: Multidisciplinary management of brain metastases. Onccologist 2007, 12(7):884-898.
• [5]Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295(21):2483-2491.
• [6]Markesbery WR, Brooks WH, Gupta GD, Young AB: Treatment for patients with cerebral metastases. Arch Neurol 1978, 35(11):754-756.
• [7]Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980, 6(1):1-9.
• [8]Roos DE: What is the randomised evidence for surgery and stereotactic radiosurgery for patients with solitary (or few) brain metastases? Int J Evid Based Healthc 2011, 9(1):61-66.
• [9]Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999, 45(2):427-434.
• [10]Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W: Common Toxicity Criteria version 2.0: an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000, 47(1):13-47.
• [11]Chougule PB, Burton-Williams M, Saris S, Zheng Z, Ponte B, Noren G, Alderson L, Friehs G, Wazer D, Epstein M: Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both. (Abst). Int J Radiat Oncol Biol Phys 2000, 48(3):114. 1 Suppl
• [12]Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP: Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1–3 cerebral metastases: Results of the EORTC 22952–26001 study. J Clin Oncol 2011, 29(2):134-141.
• [13]Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran WJ Jr: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
• [14]Chang EL, Wefel JS, Hess KP, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044.